​Changes to medical policy on patisiran (Onpattro®) and vutrisiran (Amvuttra™)

March 14, 2023

​Effective June 12, 2023, Independence Blue Cross and Independence Administrators will update their medical policy on patisiran (Onpattro®) and vutrisiran (Amvuttra™) for both Commercial and Medicare Advantage members.

This policy will be updated to include a new drug, vutrisiran (Amvuttra™), which was approved by the U.S. Food and Drug Administration in June 2022 and has coverage criteria that needs to be met. The updated policy will also include more coverage changes for patisiran (Onpattro®), including the restriction of combination therapies with drugs that act similarly.

For more information, please view the following notifications that were published on March 14, 2023: